Teaching experience: Inequalities in prices of drugs to fight against COVID-19

• Autores: Cristina Vilaplana-Prieto
• Localización: 7th International Conference on Higher Education Advances (HEAd'21) / Josep Domènech i de Soria (aut.), Paloma Merello Giménez (aut.), Elena de la Poza Plaza (aut.), 2021, ISBN 9788490489758, págs. 1219-1227
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • As the Sars-CoV2 pandemic continues to grow, researchers around the world are urgently seeking new treatments to prevent infection, cure those infected, or lessen the severity of the disease. Although there are several recently approved vaccines, clinical trials are underway to "re-use" drugs normally indicated for other diseases. This teaching experience studies the market for 8 pharmaceutical products used to fight the pandemic (remdesivir, favipiravir, lopinavir/ritonavir, chloroquine, hydroxychloroquine, sofosbuvir, pyrfenidone and tocilizumab) in 13 countries (Bangladesh, Brazil, China, Egypt, France, India, Malaysia, Pakistan, South Africa, Sweden, Turkey, United Kingdom and United States). Through the analysis of prices and costs, we reflect on the difficulty of access to treatment according to the country.The objective is to deepen knowledge of the pharmaceutical market: (i) to demonstrate in a tangible way the differences between production costs and final prices of medicines, (ii) to perceive the difficulty of access to certain treatments depending on the country, (iii) to reflect on what initiatives should be implemented in an international emergency context such as the one we are experiencing